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Ischemic Post Conditioning Protects Both Adult and Aged Sprague Dawley
Rat Hearts from Ischemia/Reperfusion Injury Through the PI3K/Akt and
eNOS Pathway
Yang Cao1
1The First Afﬁliated Hospital of Harbin Medical University, China
BACKGROUND Ischemic heart disease is considered to be one of the
most common and severe disease in elder people. In recent years the
trend of its incidence increased year by year. The world health orga-
nization (who) predicts that by 2020, ischemic heart disease will
replace infectious diseases as the world’s most deadly diseases.
Nowadays, it is still the key factor whether you open the occlusion of
coronary arteries in time that you can effectively restore the blood
perfusion of ischemic myocardium, is to limit and reduce myocardial
infarction size, which is also the key to improve prognosis. With
development of thrombolysis therapy and percutaneous coronary
intervention (PCI) the ischemic heart disease such as coronary heart
disease, acute myocardial infarction has a better prognosis now. But
occlusion of coronary artery recanalization, ischemic myocardial tis-
sue after reperfusion which caused myocardial ischemia-reperfusion
injury (Ischemia reperfusion injury, IRI) kind of inﬂuence the treat-
ment effect. Therefore, how to reduce the reperfusion injury, pro-
tection of ischemic myocardium has become the important research
content. The concept of ischemic pre-conditioning, ischemic post-
conditioning offered a possible way to protect and alleviate myo-
cardial ischemia-reperfusion injury. Since 2003 after ischemic
preconditioning concept to today, from laboratory to clinical, a large
number of animal experiments and clinical studies conﬁrmed that the
adaptation after ischemia as a kind of effective and feasible means to
provide many beneﬁts for patients with acute myocardial ischemia.
However, questions about adaptation after ischemia has not
completely solved, adaptive to reperfusion injury after ischemia
protection research mostly built on health animal models, and in
sugar or fat, the role of the elderly and other pathologic conditions
remains to be studied. Aging condition of ischemia effect how to
adapt to the heart of the protection is still controversial.
METHODS
Object
To study the protective effect of ischemia post-conditioning on rat’s
acute myocardial ischemia/reperfusion(I／R)injury and the mecha-
nism of Akt and eNOS through the cardiac protection.
Methods
Using the Langendorff reperfusion system to establish an ex vivo rat
model of whole heart ischemia/reperfusion. Use Multi-conductive
physiological recorder to record cardiac fuction as CF、HR、LVDP、
dp/dt max of all groups were recorded. Six rat hearts of each group
were used to determine myocardial infarct size by dual staining with
triphenyltetrazolium chloride and Evan’s blue dye. The other rabbits
of each group were saved for western blotting analysis as the
expression of Akt、P-Akt、eNOS and P-eNOS.
RESULTS 1) The cardiac function (LVDP anddp/dtmax) of adult/aged
IPoc group was signiﬁcantly better than that of the IRI group (P<0.05).
2) The infarction area of adult/aged IPoc group was smaller than that
of the IRI group (P<0.05). 3) The expression of P-Akt and P-eNOS of all
adult/aged IPoc groups was signiﬁcantly higher than that of the IRI
groups (P<0.05).
CONCLUSION 1) Given the post condition dispose at the very begin-
ning of the reperfusion can active PI3K-Akt and eNOS kinase to
establish the cardiac protect function, which can reduce infarct size
and improve cardiac function on both adult and aged Wistar rat heart.
2) The post condition procedure active Akt and enos through phos-
phorylation.
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Longitudinal Stent Elongation: Is Stent Elongation Occurs in Our Daily
Practice?
Akihiko Matsumura1
1Kameda Medical Center, jp
BACKGROUND We experienced two cases of longitudinal stent elon-
gation (LSE) during stent deployment and disclose that LSE occurs
when stents were expanded in air pressure and in malapposition
vessel models.
METHODS Following tests were performed to disclose the occurrence
LSE.
Test1: Five kinds of drug eluting stents (DES: Xience Xpedition
(XPD), Plomus Premier (PP), Nobori (N), Resolute Integrity (RI) andCypher select plus (CY)) with three 3x28 or 3x26mm stents of each
were used. All stents were implanted in a phantom model with the
diameter being 3mm at nominal pressure achieving good apposition
and single post-dilation to mid portion of the stents was performed
using 3.5x15mm high-pressure balloon catheter (HP) at rated burst
pressure (RBP).
Test2: All stents except CY were dilated three times at RBP in air
pressure (non-stenotic model). Secondary, the tube 2mm in diameter
and 5mm in length were put on the stents and stents were dilated
three times at RBP in air pressure (stenotic model).
Test3: Three 3 x 28mm Multilink Vision stents put on the tube 2mm
in diameter and 5mm length (Short) or 15mm length (Long) of each
were dilated three times at RBP in air pressure.
RESULTS Four new DESssigniﬁcantly elongated than CY in a apposi-
tion phantom model and less elongatedat the stenotic model
than non-stenotic model. Moreover, stent elongationdepends on the
stenotic length, namely, stents elongated less at the longstenotic
lesions.Test 1 (mm) XPD PP N RI CY102.9  0.21 102.54  0.71 102.07  0.26 103.42  0.44 100.3  0.51 P < 0.05Test 2 (mm) NON-STENOTIC STENOTIC109.89  2.41 108.79  1.88 P < 0.05Test 3 (mm) Short Long108.26  0.03 105.01  0.22 P < 0.05CONCLUSION LSE was observed all kinds of DESs especially in new
generation ones in apposition model. However, it seems to less
common in the long stenotic lesions.BIFURCATION AND LEFT MAIN STENTING (TCTAP A-143)
TCTAP A-143
Left Main PCI in a Peripheral Centre Without IABP: Immediate and Long
Term Results
Gurunath P. Parale1
1Ashwini Cooperative Hospital, India
BACKGROUND Interventional cardiologist occasionally comes across
patients with critical lt. main lesions who are either hemodynamically
compromised or have severe angina, ECG changes warranting urgent
PCI especially if urgent CABG cannot be done. This is particularly
challenging in peripheral center with limited resources and facilities.
This study is aimed to study feasibility, efﬁcacy, and long term results
of left main PCI in peripheral center. First left main PCI was done as
PAMI in cardiac arrest survivor in cardiogenic shock. He had total left
main off. He miraculously survived. Subsequent left main PCI pro-
cedures though predominantly were salvage later were done on
elective basis.
METHODS A total of 27 patients underwent Left Main PTCA at
Ashwini Sahakari Rugnalaya, Solapur, a semi-urban area of Mahara-
shtra. 1stLeft Main PTCA was done on 16/02/2008 and last on 01/04/
2014. Initially left main PTCA was done only as a rescue lifesaving or
as primary intervention in STEMI. Subsequently it was also done as
elective procedure when anatomy was suitable. Out of 27, 19 were
males and 8 females, age ranged from 35 years to 91 years with mean
age of 60.4. Left main as rescue procedure was done in 17 patients
when immediately after CAG patient had either severe chest pain,
hemodynamic compromise and in 1 patient dissection of left main. In
7 patients left main was done as PAMI for STEMI and in 2 patients it
was an elective procedure. IABP was not used in any patient.
RESULTS Lesion location: ostial – 16, shaft – 04, terminal – 07.
No of stents: Left main alone – 04, Left main with crossover to LAD
single stent – 14,Left main with LAD separate stents– 02,Left main
with CX – 02,Left main with RCA – 01,Left main with LAD & CX–
01,Left main with LAD & RCA – 03.1 patient had TIMI II ﬂow ,others
had good on table result. Clinical or telephonic follow-up was avail-
able in all patients and ranged from 4 months to 6 years. 2 patients
had follow-up angiogram .Of the 2 PCI related deaths, 1 had TIMI II
ﬂow after PCI and other was in shock at the time of PCI. Both died in
hospital. Of the 3 PCI unrelated deaths 1 patient was having chronic
renal failure, stopped dialysis and died.1 patient died of refractory
heart failure 1 year later.1 patient stopped medication after 1 month
and had sudden death. 1 patient 3 years later had angina, ECG changes
and developed signiﬁcant re-stenosis of stent for which he success-
fully underwent CABG surgery.
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with good long term results even in a peripheral center.
Left main coronary patients usually present in hemodynamically
compromised state warranting immediate intervention not giving
enough time to shift to well-equipped center in metro cities. This
study should bolster the conﬁdence of those working in periphery to
undertake left main interventions especially in rescue situations to
save lives.CELL THERAPY AND ANGIOGENESIS (TCTAP A-144)
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Globular Adiponetin Protects Mesenchymal Stem Cells Against Hypoxia
and Serum Deprivation Induced Apoptosis via the AdipoR1/AMPK Pathway
Xiaqiu Tian,1 Yuejin Yang1
1Fuwai Hospital, CAMS&PUMC, China
BACKGROUND Bone marrow-derived mesenchymal stem cells (MSCs)
transplantation is a promising therapy for cardiac repair. However,
poor viability of transplanted MSCs within the ischemic heart has
limited their therapeutic potential. Hypoxia and serum deprivation
(H/SD) was widely used to mimic the ischemic myocardium micro-
environment and induced MSCs apoptosis through the mitochondrial
apoptotic pathway. Adiponectin (APN) is an adipocyte-secreted adi-
pokine with pleiotropic actions. Accumulating evidence suggests that
the physiological roles of APN go beyond its metabolic effects and
participate in tissue regeneration and promote the survival of several
other stem cells. We embarked on investigating the role of APN in the
prevention of MSCs against H/SD-induced apoptosis and elucidated
the potential mechanisms involved.
METHODS Rat bone marrow MSCs were exposed to H/SD with
different concentrations (0, 0.01, 0.1, 1 ug/ml) of globular APN in a
sealed GENbox hypoxic chamber for 12 hours. MSCs were transfected
with adiponectin receptors 1 and 2 (AdipoR1 and AdipoR2) siRNAs to
determine the major receptor type that mediated the actions of APN.
For pathway studies, the cells were pre-incubated with AMPK inhib-
itor Compound C. Apoptosis was detected by Annexin V staining and
measuring caspase-3 activity. Mitochondrial dysfunction was
analyzed by measuring expression of Bcl-2 and Bax.
RESULTS H/SD-induced apoptosis was attenuated by globular APN
in a concentration-dependent manner evidenced by reduced
Annexin V stained positive cells and decreased caspase-3 activity.
This protective effect of APN was mainly mediated through AdipoR1.
Moreover, APN increased the phosphorylation of AMPK and Com-
pound C effectively reversed the anti-apoptotic effect of APN.
Furthermore, APN signiﬁcantly increased the expression of Bcl-2 and
decreased Bax expression. The inhibition of the AdipoR1 or AMPK
pathway partly abolished the effect of APN on mitochondrial
dysfunction.
CONCLUSION These data demonstrated that globular APN prevents
H/SD - induced apoptosis and mitochondrial dysfunction in MSCs via
AdipoR1 linked to the activation of downstream AMPK pathway. Our
ﬁndings indicate that APN is a novel, potent survival factor for MSCs
in the ischemic myocardium.COMPLEX (TCTAP A-145 TO TCTAP A-146)
TCTAP A-145
Virtual 5-French Intra-Aortic Pumping Using a Glidesheath Slender and
6-French Intra-Aortic Balloon Catheter
Norimasa Taniguchi1
1Sakurakai Takahashi Hospital, Japan
BACKGROUND In recent years, major technical advances in intra-
aortic balloon pumping (IABP) catheters have beenmade, including the
introduction of low-proﬁle catheters and the use of percutaneous
insertion through a sheath introducer. To date, many clinical studies
have conﬁrmed the impact of lower proﬁle IABP catheters on the inci-
dence of vascular complications. Recently, the 6-Fr IABP catheter was
introduced for clinical use in Japan, and its feasibility and efﬁcacy have
already been reported; it is expected to further reduce the incidence of
access site complications, For the insertion of 6-Fr IABP catheters,
usually the dedicated 6-Fr sheath introducer is used; however, with the
recent development of sheath introducers, the use of the 6-Fr sheath
introducer, which has a thinner wall structure and the same outer
diameter compared to the conventional 5-Fr introducer, has been
established for percutaneous coronary intervention (PCI). Thisintroducer is currently distributed for trans-radial access only, as itmay
kink in the absence of a guiding catheter or inner sheath if used for the
brachial or femoral approach owing to its very thin size. However, we
hypothesize that this introducer can be safely used for the 6-Fr IABP, as
the caliber of the puncture site becomes virtually 5-Fr, and that thismay
contribute to further reduction of access site complications, thus
allowing early ambulation of patients undergoing coronary interven-
tion. Accordingly, in this study, we evaluated the feasibility of hemo-
dynamic support with 6-Fr IABP catheters during PCI, using this sheath
introducerwith thinwall structure. To the best of our knowledge, this is
theﬁrst feasibility study for application of theGlide sheath Slenderwith
the 6-Fr IABP catheter.
METHODS Between May 2014 and October 2014, 13 patients with
acute coronary syndrome underwent percutaneous coronary
intervention (PCI) using a 6-Fr IABP catheter through a6-Fr Glide
sheath Slender for support. The adverse events, including access
site complications, kinking of the sheath during the procedure,
and any evidence of balloon pump failure, were retrospectively
investigated.
RESULTS Baseline characteristics of the patients and insertion procedure.
A total of 13 patients were evaluated. The mean age of the patients
was 70.1years and all patients were men. The mean height and body
weight were 164.2 cm and 66.1 kg, respectively. The insertion and
subsequent balloon pumping were successful in all cases. The IABP
catheter was inserted through the femoral artery in 12 (92.3%) patients
and through the left brachial artery in 1 (7.7%) patient for whom the
femoral approach was contraindicated (Fig. 1-5). The mean support
time was 26.4  16.3 h. Kinking of the introducer shaft occurred during
the insertion procedure in one patient; however, the subsequent
balloon pumping was well maintained and did not require exchange of
the sheath or IABP catheter. In another case, strong resistance was
observed during IABP catheter insertion in the sheath, probably owing
to incomplete vacuum suction during preparation of the IABP catheter.
Complications
No patient experienced major access site bleeding; however, 1 pa-
tient who underwent trans brachial insertion experienced minor
bleeding in the approach site. No patient developed severe limb
ischemia. Helium leakage or poor helium inﬂation necessitating
catheter exchange did not occur in any case. One patient, who was
undergoing extracorporeal membrane oxygenation, experienced car-
diopulmonary arrest outside the hospital and subsequently died of
multi-organ failure. However, no death related to the IABP catheter
insertion was observed.
CONCLUSION Although it has several limitations, the use of the 6-Fr
IABP catheter through a 6-Fr slender sheath resolved issues related to
approach site limitations and access site-related complications.
Further investigations are required to conﬁrm our ﬁndings.
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LAD Ostial PCI : An Innovative Technique
Afzalur Rahman,1 Mohammad Mahbubur Rahman,1
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BACKGROUND Ostial left anterior descending coronary artery (LAD)
lesion is an important target for coronary revascularization because
its location subtends a large territory of myocardium. An ostial
stenosisis an angiographic narrowing of  70% located within 3 mm
of the vessel origin. Ostial lesions have a reputation of being ﬁbrotic,
calciﬁed, and relatively rigid. Ostial disease is felt to be additionally
resistant to dilatation and prone to recoil due to the greater thick-
ness of muscular and elastic tissue in the aortic wall. Greater degrees
of rigidity and recoil resulted in lower acute gain and higher rates of
TLR. In addition, procedural complications such as dissections,
vessel closure and myocardial infarction were more frequent. Stra-
tegies for LAD Ostial PCI are Proximal strut of stent extended into
distal LM, Stenting Covering the Distal LMCA, Precise Location at
Ostium.
Sometime Stent placement may be difﬁcult due to excessive stent
movement Aim of the study was to evaluate a simple an innovative
technique to deal with signiﬁcant LAD ostial lesion. (Fig 1- LAD ostial
stenosis)
